Feed Articles

Pfizer posts positive third quarter results despite challenges

Pfizer, the well-known US pharmaceutical company, continues to face pressure from activist investor Starboard. Despite facing a significant decline in sales of its COVID-19-related products, the third quarter of 2024 delivered a positive surprise in the form of results that beat market expectations.

Sales of Paxlovide, the antiviral Pfizer $PFE developed to treat COVID-19, exceeded Wall Street expectations, contributing to the company's positive stock performance.

Pfizer reported third-quarter sales of $17.70 billion, which was more than expected ($14.96 billion). This positive result was mainly boosted by sales of Paxlovide, which generated $2.7 billion in the period, while analysts had predicted sales of only $456.4 million.

The company's CEO, Albert Bourla, said in prepared statements that demand for Paxlovide has stabilized and is closely related to each wave of COVID-19. He also added that strong commercial performance and higher infection rates contributed to the better-than-expected results.

Pfizer also decided to raise its full-year profit and sales forecasts. It expects revenue from Comirnata (COVID-19 vaccine) and Paxlovide to reach $10.5 billion, up from its previous forecast of $8.5 billion. Comirnata vaccine sales reached $1.42 billion for the quarter, again beating analysts' expectations, who had forecast $870 million.

Activist hedge fund Starboard Value, as well as investors and analysts, have expressed the need to see improvement in profitability due to cost savings and revenue growth from recent deals. Pfizer also raised its earnings-per-share estimates to $2.75 to $2.95, up from a previous forecast of $2.45 to $2.65. On an adjusted basis, Pfizer reported earnings of $1.06 per share, beating analysts' average estimate of 62 cents.

Although Pfizer stock is still trading at about half of its pandemic highs, the latest results show the company is on track to restore growth and stability in turbulent times.

Disclaimer: There is plenty of inspiration to be found on Bulios, but stock selection and portfolio construction is up to you, so always conduct a thorough analysis of your own.

Source: CNN, Yahoo, Reuters.

Stocks mentioned

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

These 3 Stocks Raised Their Dividends During the 2008 Crisis and COVID. One Pays Every Month

When companies were canceling shareholder payouts in 2009 and again during the pandemic, these three railway companies were raising them instead. Today they offer yields of 2.1% to 5.7% a year.

MC
Milan Charvat
· 6h
Read more
BLACK

She designs drugs with AI, and Cathie Wood wanted her at $16. Today it's $14

An AI-designed cancer drug reached patients in two years. Its maker raised $172 million on the stock market, and funds linked to Cathie Wood and Druckenmiller wanted shares. Then the price fell 62% in three weeks.

KJ
Kryštof Jáně
· 10h
Read more
BLACK

Americans Have Stopped Buying on Credit. Which Stocks Will Take the Hit?

The monthly payment on a new car in the US has climbed to $823, and auto dealers' sales fell 1.6% in October. In the same week, Target reported its fastest sales growth in five years. Meanwhile, the market expects the Fed to make credit even more expensive in three weeks.

MC
Milan Charvat
· 11h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy